Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-19 01:15 • The Motley Fool Positive Axe Cap view: Selective

As Meta and other tech giants rapidly expand AI data center capacity, industrial suppliers Caterpillar and Eaton are experiencing significant growth. Caterpillar's backlog reached a record $63 billion (up 79% year-over-year) driven by demand for earth-moving equipment and power generators, while Eaton's Americas division backlog grew over 40% with order growth at 60%, fueled by AI infrastructure demand. Both companies are well-positioned to benefit from the ongoing data center construction boom, though their valuations are elevated at 45x and 38x P/E ratios respectively.

Axe note: AI-driven data center building is boosting industrial suppliers—but South Africa must watch the rand and banks closely.

2026-07-19 00:30 • The Motley Fool Positive Axe Cap view: Selective

Chubb, the world's largest publicly traded property and casualty insurer, trades at a 12x P/E ratio compared to the S&P 500's 32x multiple, suggesting potential undervaluation. The company has delivered 226% total returns over the past decade and expects continued growth through middle-market expansion, AI upgrades, and higher fixed-income yields. With a 33-year dividend increase streak and a $7.5 billion buyback authorization, Chubb appears to be a stable, defensive investment opportunity.

Axe note: Chubb trades at a low multiple with steady dividends and growth prospects, presenting a rare value in insurance.

2026-07-19 00:16 • The Motley Fool Positive Axe Cap view: Selective

The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.

Axe note: Comparing concentrated U.S. pharma ETF IHE against diversified global healthcare ETF IXJ through a South African lens.